title: Therapy Development for the Lysosomal Storage Disease Fucosidosis using the Canine Animal Model.
abstract: Abstract Fucosidosis (OMIM 23000) is an inherited neurodegenerative lysosomal storage disease caused by a deficiency of the lysosomal hydrolase a-L-fucosidase due to mutations in the FUCA1 gene. Without enzyme-targeted therapy patients rarely survive beyond the first decade of life, and therapy options other than supportive care are limited. Hematopoietic transplants, first developed in the fucosidosis dog model, are the only treatment option available capable of delaying the disease course. However, due to the risks and exclusion criteria of this treatment additional therapies are required. The development of additional therapies including intravenous and intra-cerebrospinal fluid enzyme replacement therapy and gene therapy, which have been trialed in the canine model, will be discussed.
authors.forename: Jessica L
authors.initials: JL
authors.lastname: Fletcher
authors.forename: Rosanne M
authors.initials: RM
authors.lastname: Taylor
mesh_terms: D000818:Animals; D003131:Combined Modality Therapy; D004195:Disease Models, Animal; D004285:Dogs; D056947:Enzyme Replacement Therapy; D005645:Fucosidosis / Q000628:therapy*; D015316:Genetic Therapy; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D005644:alpha-L-Fucosidase / Q000235:genetics / Q000627:therapeutic use*
chemical_list: D005644:alpha-L-Fucosidase